What are alternative treatments to a canagliflozin (Invokana) 100 mg tablet?

Alternative Treatments to Invokana (Canagliflozin) 100 mg

For patients requiring an alternative to canagliflozin 100 mg, the choice depends primarily on whether cardiovascular disease, heart failure, or chronic kidney disease is present—if so, prioritize other SGLT2 inhibitors (empagliflozin, dapagliflozin) or GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) with proven cardiovascular and renal benefits; if not, consider DPP-4 inhibitors or sulfonylureas based on cost and hypoglycemia risk tolerance. 1

Decision Algorithm Based on Comorbidities

If Patient Has ASCVD, Heart Failure, or CKD (eGFR 30-60 mL/min/1.73 m²):

First-line alternatives:

• Other SGLT2 inhibitors with cardiovascular/renal benefits 1:

  • Empagliflozin 10-25 mg daily (proven MACE reduction and HF benefit)
  • Dapagliflozin 10 mg daily (proven MACE reduction and HF benefit)
  • These agents provide similar glucose-lowering efficacy (intermediate to high) with documented cardiovascular and kidney protection 1

• GLP-1 receptor agonists (if SGLT2 inhibitors contraindicated or additional glucose lowering needed) 1:

  • Semaglutide 0.5-1 mg weekly (highest glucose-lowering efficacy, proven MACE benefit)
  • Liraglutide 1.2-1.8 mg daily (proven MACE benefit)
  • Dulaglutide 1.5-4.5 mg weekly (proven MACE benefit)
  • These provide high to very high glucose-lowering efficacy with weight loss and cardiovascular protection 1

Rationale: The 2025 ADA guidelines explicitly prioritize medications with proven cardiovascular and renal benefits in patients with established complications 1. Both SGLT2 inhibitors and GLP-1 RAs reduce major adverse cardiovascular events, with emerging data suggesting combination therapy provides complementary benefits 2.

If Patient Has NO Cardiovascular Disease or CKD:

Consider these alternatives based on specific needs:

• DPP-4 inhibitors (if hypoglycemia avoidance and neutral weight effect desired):

  • Sitagliptin 100 mg daily
  • Comparable glucose-lowering to canagliflozin 100 mg 3
  • No hypoglycemia risk, weight neutral, well-tolerated 1

• Sulfonylureas (if cost is primary concern):

  • Glimepiride 1-8 mg daily
  • Similar HbA1c reduction to canagliflozin 100 mg (both achieved ~7.0% final HbA1c from 7.8% baseline) 4
  • Major caveat: Causes weight gain (+0.7 kg vs -3.7 kg with canagliflozin 100 mg) and significantly higher hypoglycemia risk 4

• Metformin intensification (if not at maximum dose):

  • Increase to 2000 mg daily if tolerated
  • High glucose-lowering efficacy, weight neutral to modest loss, cardiovascular benefit suggested 1

Comparative Efficacy Data

From head-to-head trials, canagliflozin 100 mg demonstrated 3, 4:

• HbA1c reduction: -0.77% from baseline (vs placebo +0.14%)
• Weight loss: -2.8% body weight (-2.2 kg more than placebo)
• Blood pressure: -3.7 mmHg systolic reduction
• Comparable efficacy to: Sitagliptin 100 mg and glimepiride 6-8 mg for glucose control

Important distinction: Canagliflozin 300 mg provides superior glucose lowering compared to 100 mg (HbA1c reduction -1.03% vs -0.77%), but both doses show similar cardiovascular and renal benefits 5, 6.

Safety Considerations When Switching

Avoid SGLT2 inhibitors (including alternatives) if:

• History of recurrent genital mycotic infections
• High risk for diabetic ketoacidosis (insulin-deficient states)
• History of lower limb amputation or active foot ulcers 3
• eGFR <30 mL/min/1.73 m² (contraindicated) 1
• Volume depletion or on high-dose loop diuretics without correction 3

Avoid GLP-1 RAs if:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• History of pancreatitis (relative contraindication) 1
• Severe gastroparesis

Avoid sulfonylureas if:

• High hypoglycemia risk (elderly, erratic eating, renal impairment)
• Weight loss is a treatment goal
• Operating heavy machinery or driving professionally 1

Practical Switching Approach

1. Stop canagliflozin (no washout period needed for most alternatives)
2. Start alternative at standard initial dose:
   • SGLT2 inhibitors: Begin at lowest dose, can uptitrate
   • GLP-1 RAs: Follow dose escalation protocols to minimize GI side effects
   • DPP-4 inhibitors: Start at full dose
   • Sulfonylureas: Start low, titrate based on glucose response
3. Monitor glucose closely for 1-2 weeks, especially if switching to agents with different efficacy profiles
4. Adjust insulin/secretagogue doses if present to prevent hypoglycemia 1

Cost Considerations

Based on 2022 pricing data 2:

• Most expensive: GLP-1 RAs ($727-$975 per month)
• Moderate cost: SGLT2 inhibitors ($297-$526 per month, canagliflozin among least expensive)
• Least expensive: Sulfonylureas, DPP-4 inhibitors (generic options available)

The most recent evidence strongly favors SGLT2 inhibitors or GLP-1 RAs as alternatives when cardiovascular or renal protection is needed, despite higher costs, given their proven mortality and morbidity benefits 1.